Denali Therapeutics Receives FDA Breakthrough Therapy Designation For Tividenofusp Alfa In Treatment Of Hunter Syndrome (MPS II)

BenzingaJan 8 21:01

Express News | Denali Therapeutics Inc - Expects to Submit Bla for Tividenofusp Alfa in Early 2025

BreakingsJan 8 21:00

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

GlobeNewswireJan 8 21:00

Denali Therapeutics Price Target Lowered to $32 From $35 at BTIG

Yahoo FinanceJan 8 20:25

Denali Therapeutics Is Maintained at Overweight by JP Morgan

Dow JonesJan 8 03:20 · Ratings

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

Zacks Jan 8 02:30